Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
NCT05023655Phase 2Terminated
- Sponsor
- Prisma Health
- Start
- Jan 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tazemetostat in solid tumor, sponsored by Prisma Health. Started Jan 2022; status: terminated.
02
Drugs
tazemetostat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05023655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05023655.